Targeted tablet approved for ESR1-positive breast cancer
- Mar 1
- 2 min read
A targeted oral treatment has been approved for use in people with ESR1-positive breast cancer, marking a significant development in the treatment of hormone receptor–positive disease. The decision reflects growing recognition that breast cancer is not a single condition, but a group of biologically distinct subtypes that respond differently to treatment.
ESR1 mutations affect the oestrogen receptor and are most commonly seen in people with advanced or metastatic breast cancer who have previously received hormone therapy. These mutations can make standard endocrine treatments, such as aromatase inhibitors, less effective over time. Until recently, treatment options after resistance developed were limited.
The newly approved tablet is designed to specifically target cancers driven by ESR1 mutations. Rather than blocking oestrogen production, it works by degrading the oestrogen receptor itself, reducing the cancer’s ability to use hormonal signalling to grow. This mechanism offers an alternative approach for patients whose disease has progressed despite earlier hormone-based treatments.
Approval has been based on clinical trial data showing improved progression-free survival compared with standard endocrine therapies in people with confirmed ESR1 mutations. Importantly, the treatment is taken orally, which may reduce the need for regular injections or hospital-based administration.
This development highlights the increasing role of molecular testing in cancer care. Identifying ESR1 mutations requires genomic analysis of tumour tissue or circulating tumour DNA from blood samples. As targeted therapies expand, access to timely and accurate testing becomes central to ensuring patients receive the most appropriate treatment for their cancer subtype.
While the approval represents progress, it also raises practical considerations. Not all patients will be eligible, and the treatment is intended for a specific stage of disease rather than early breast cancer. Side effects, long-term effectiveness, and sequencing with other treatments will continue to be monitored as use becomes more widespread.
From a system perspective, the decision reflects a broader shift towards personalised oncology, where treatments are matched to tumour biology rather than applied uniformly. This approach has the potential to improve outcomes while also reducing exposure to therapies that are unlikely to be effective.
For patients, the approval may offer renewed options at a point when treatment choices can feel increasingly limited. It also reinforces the importance of ongoing review and reassessment in cancer care, particularly as resistance to treatment can develop over time.
As targeted therapies continue to emerge, breast cancer treatment is becoming more precise, but also more complex. Clear communication, access to testing, and shared decision-making remain essential in helping patients understand what these advances mean for their individual care.